Cambridge drug trial hopes to slow Parkinson’s disease

Dr Williams-Gray, who is also an honorary consultant neurologist at Addenbrooke’s, said: “There is a pressing need for a specific treatment, such as dapansutrile, which targets the most relevant aspects of the immune activation pathway in Parkinson’s, without causing general immunosuppression and leading to unwanted side-effects.”